Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Lysyl Oxidase is a key player in BRAF/MAPK pathway-driven thyroid cancer aggressiveness.

Boufraqech M, Patel D, Nilubol N, Powers AS, King T, Shell J, Lack J, Zhang L, Gara SK, Gunda V, Klubo-Gwiezdzinska J, Kumar S, Fagin JA, Knauf J, Parangi S, Venzon DJ, Quezado M, Kebebew E.

Thyroid. 2018 Nov 6. doi: 10.1089/thy.2018.0424. [Epub ahead of print]

PMID:
30398411
2.

Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.

Nilubol N, Boufraqech M, Zhang L, Gaskins K, Shen M, Zhang YQ, Gara SK, Austin CP, Kebebew E.

Oncotarget. 2018 Aug 31;9(68):33030-33042. doi: 10.18632/oncotarget.26050. eCollection 2018 Aug 31.

3.

68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor.

Shell J, Keutgen XM, Millo C, Nilubol N, Patel D, Sadowski S, Boufraqech M, Yang L, Merkel R, Atallah C, Herscovitch P, Kebebew E.

Int J Endocr Oncol. 2018 Feb 2;5(1):IJE04. doi: 10.2217/ije-2017-0005. eCollection 2018 Feb.

4.

Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo.

Thakur S, Daley B, Gaskins K, Vasko VV, Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, Agarwal S, Klubo-Gwiezdzinska J.

Clin Cancer Res. 2018 Aug 15;24(16):4030-4043. doi: 10.1158/1078-0432.CCR-17-3167. Epub 2018 Apr 24.

5.

Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.

Keutgen XM, Kumar S, Gara S, Boufraqech M, Agarwal S, Hruban RH, Nilubol N, Quezado M, Finney R, Cam M, Kebebew E.

Cancer. 2018 Feb 1;124(3):636-647. doi: 10.1002/cncr.31057. Epub 2017 Nov 17. Erratum in: Cancer. 2018 Apr 1;124(7):1518.

PMID:
29149451
6.

Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.

Kotian S, Zhang L, Boufraqech M, Gaskins K, Gara SK, Quezado M, Nilubol N, Kebebew E.

Clin Cancer Res. 2017 Sep 1;23(17):5044-5054. doi: 10.1158/1078-0432.CCR-17-1043. Epub 2017 Jun 9.

7.

MicroRNAs in the thyroid.

Boufraqech M, Klubo-Gwiezdzinska J, Kebebew E.

Best Pract Res Clin Endocrinol Metab. 2016 Oct;30(5):603-619. doi: 10.1016/j.beem.2016.10.001. Epub 2016 Nov 1. Review.

8.

LOX is a novel mitotic spindle-associated protein essential for mitosis.

Boufraqech M, Wei D, Weyemi U, Zhang L, Quezado M, Kalab P, Kebebew E.

Oncotarget. 2016 May 17;7(20):29023-35. doi: 10.18632/oncotarget.8628.

9.

Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.

Boufraqech M, Zhang L, Nilubol N, Sadowski SM, Kotian S, Quezado M, Kebebew E.

Clin Cancer Res. 2016 Sep 1;22(17):4491-504. doi: 10.1158/1078-0432.CCR-15-2461. Epub 2016 Mar 30.

10.

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.

Zhang L, Boufraqech M, Lake R, Kebebew E.

Oncotarget. 2016 Mar 29;7(13):16517-28. doi: 10.18632/oncotarget.7760.

11.

The histone variant H2A.X is a regulator of the epithelial-mesenchymal transition.

Weyemi U, Redon CE, Choudhuri R, Aziz T, Maeda D, Boufraqech M, Parekh PR, Sethi TK, Kasoji M, Abrams N, Merchant A, Rajapakse VN, Bonner WM.

Nat Commun. 2016 Feb 15;7:10711. doi: 10.1038/ncomms10711.

12.

Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.

Satoh K, Zhang L, Zhang Y, Chelluri R, Boufraqech M, Nilubol N, Patel D, Shen M, Kebebew E.

Clin Cancer Res. 2016 Jul 15;22(14):3458-66. doi: 10.1158/1078-0432.CCR-15-2256. Epub 2016 Feb 12.

13.

Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.

Gara SK, Wang Y, Patel D, Liu-Chittenden Y, Jain M, Boufraqech M, Zhang L, Meltzer PS, Kebebew E.

Nucleic Acids Res. 2015 Oct 30;43(19):9327-39. doi: 10.1093/nar/gkv908. Epub 2015 Oct 7.

14.

FDG PET/CT Scan and Functional Adrenal Tumors: A Pilot Study for Lateralization.

Patel D, Gara SK, Ellis RJ, Boufraqech M, Nilubol N, Millo C, Stratakis CA, Kebebew E.

World J Surg. 2016 Mar;40(3):683-9. doi: 10.1007/s00268-015-3242-y.

PMID:
26324161
15.

New genomic somatic amplifications and deletions in papillary thyroid cancer.

Boufraqech M, Kebebew E.

Endocrine. 2015 Nov;50(2):270-1. doi: 10.1007/s12020-015-0704-9. Epub 2015 Jul 30. No abstract available.

16.

Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.

Mehta A, Zhang L, Boufraqech M, Zhang Y, Patel D, Shen M, Kebebew E.

Endocr Relat Cancer. 2015 Jun;22(3):319-29. doi: 10.1530/ERC-14-0510.

PMID:
25972243
17.

Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.

Sadowski SM, Boufraqech M, Zhang L, Mehta A, Kapur P, Zhang Y, Li Z, Shen M, Kebebew E.

Oncotarget. 2015 Jul 20;6(20):18038-49.

18.

Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.

Mehta A, Zhang L, Boufraqech M, Liu-Chittenden Y, Zhang Y, Patel D, Davis S, Rosenberg A, Ylaya K, Aufforth R, Li Z, Shen M, Kebebew E.

Clin Cancer Res. 2015 Sep 15;21(18):4123-32. doi: 10.1158/1078-0432.CCR-14-3251. Epub 2015 May 5.

19.

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.

Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, Tian Z, Yu Z, Boxer MB, Kiefer JA, Copland JA, Smallridge RC, Li Z, Shen M, Kebebew E.

Oncotarget. 2015 Apr 20;6(11):9073-85.

20.

miR30a inhibits LOX expression and anaplastic thyroid cancer progression.

Boufraqech M, Nilubol N, Zhang L, Gara SK, Sadowski SM, Mehta A, He M, Davis S, Dreiling J, Copland JA, Smallridge RC, Quezado MM, Kebebew E.

Cancer Res. 2015 Jan 15;75(2):367-77. doi: 10.1158/0008-5472.CAN-14-2304. Epub 2014 Dec 8.

21.

Hyperparathyroidism-jaw tumor syndrome: Results of operative management.

Mehta A, Patel D, Rosenberg A, Boufraqech M, Ellis RJ, Nilubol N, Quezado MM, Marx SJ, Simonds WF, Kebebew E.

Surgery. 2014 Dec;156(6):1315-24; discussion 1324-5. doi: 10.1016/j.surg.2014.08.004. Epub 2014 Oct 16.

22.

ZNF367 inhibits cancer progression and is targeted by miR-195.

Jain M, Zhang L, Boufraqech M, Liu-Chittenden Y, Bussey K, Demeure MJ, Wu X, Su L, Pacak K, Stratakis CA, Kebebew E.

PLoS One. 2014 Jul 21;9(7):e101423. doi: 10.1371/journal.pone.0101423. eCollection 2014.

23.

Analysis of IGF and IGFBP as prognostic serum biomarkers for adrenocortical carcinoma.

Patel D, Ellis R, Howard B, Boufraqech M, Gara SK, Zhang L, Quezado MM, Nilubol N, Kebebew E.

Ann Surg Oncol. 2014 Oct;21(11):3541-7. doi: 10.1245/s10434-014-3768-5. Epub 2014 May 16.

PMID:
24833102
24.

miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3.

Boufraqech M, Zhang L, Jain M, Patel D, Ellis R, Xiong Y, He M, Nilubol N, Merino MJ, Kebebew E.

Endocr Relat Cancer. 2014 Aug;21(4):517-31. doi: 10.1530/ERC-14-0077. Epub 2014 Apr 29.

PMID:
24781864
25.

Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease.

Nilubol N, Boufraqech M, Zhang L, Kebebew E.

J Clin Endocrinol Metab. 2014 Jul;99(7):E1173-82. doi: 10.1210/jc.2013-4140. Epub 2014 Mar 21.

26.

Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype.

Ellis RJ, Wang Y, Stevenson HS, Boufraqech M, Patel D, Nilubol N, Davis S, Edelman DC, Merino MJ, He M, Zhang L, Meltzer PS, Kebebew E.

J Clin Endocrinol Metab. 2014 Feb;99(2):E329-37. doi: 10.1210/jc.2013-2749. Epub 2013 Dec 11.

27.

MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.

Patel D, Boufraqech M, Jain M, Zhang L, He M, Gesuwan K, Gulati N, Nilubol N, Fojo T, Kebebew E.

Surgery. 2013 Dec;154(6):1224-8; discussion 1229. doi: 10.1016/j.surg.2013.06.022.

28.

Diagnosis of thyroid cancer: state of art.

Boufraqech M, Patel D, Xiong Y, Kebebew E.

Expert Opin Med Diagn. 2013 Jul;7(4):331-42. doi: 10.1517/17530059.2013.800481. Epub 2013 May 23. Review.

PMID:
23701167
29.

TLR-10 polymorphism and papillary thyroid cancer: one more SNP to consider?

Boufraqech M, Fassassi C, Kebebew E.

Endocrine. 2013 Feb;43(1):10-1. doi: 10.1007/s12020-012-9827-4. Epub 2012 Nov 9. No abstract available.

PMID:
23138464
30.

ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence.

Weyemi U, Lagente-Chevallier O, Boufraqech M, Prenois F, Courtin F, Caillou B, Talbot M, Dardalhon M, Al Ghuzlan A, Bidart JM, Schlumberger M, Dupuy C.

Oncogene. 2012 Mar 1;31(9):1117-29. doi: 10.1038/onc.2011.327. Epub 2011 Aug 15.

31.

Functional consequences of dual oxidase-thyroperoxidase interaction at the plasma membrane.

Fortunato RS, Lima de Souza EC, Ameziane-el Hassani R, Boufraqech M, Weyemi U, Talbot M, Lagente-Chevallier O, de Carvalho DP, Bidart JM, Schlumberger M, Dupuy C.

J Clin Endocrinol Metab. 2010 Dec;95(12):5403-11. doi: 10.1210/jc.2010-1085. Epub 2010 Sep 8.

PMID:
20826581
32.

Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells.

Ameziane-El-Hassani R, Boufraqech M, Lagente-Chevallier O, Weyemi U, Talbot M, M├ętivier D, Courtin F, Bidart JM, El Mzibri M, Schlumberger M, Dupuy C.

Cancer Res. 2010 May 15;70(10):4123-32. doi: 10.1158/0008-5472.CAN-09-4336. Epub 2010 Apr 27.

Supplemental Content

Loading ...
Support Center